Compare Salesforce Inc (CRM) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Revvity Inc — how do they compare? Salesforce Inc trades at $171.01 (market cap $137.23B), while Revvity Inc trades at $110.86 (market cap $12.41B). The key difference: Salesforce Inc is far larger — about 11.1× Revvity Inc's market cap, and Salesforce Inc pays the higher dividend (1.05%). Which is the better fit depends on your goals.
| CRM | RVTY | |
|---|---|---|
Market Cap | $137.23B | $12.41B |
Sector | Technology | Technology |
52-Week High | $270.25 | $117.75 |
52-Week Low | $150.12 | $82.26 |
Enterprise Value | $167.28B | $14.90B |
Dividend Yield | 1.05% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $171.22, up 4.84% over 24 hours, with a bullish technical signal despite mixed momentum indicators. The company demonstrates strong fundamentals, including a 77.64% gross margin and consistent earnings beats, with Q1 2026 EPS of $3.88 exceeding the $3.13 estimate. Revenue grew to $37.90B in 2025, and operating cash flow reached $13.09B. Recent news highlights AI-driven growth potential, though the stock faces sector-wide volatility.
Outlook remains positive with a consensus price target of $235.90, implying 38% upside, supported by 73 buy ratings. Risks include competitive pressures in SaaS and macroeconomic sensitivity. AI adoption and strong cash flow generation present key opportunities for long-term investors.
RVTY trades at $111.11, down 1.05% today, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.06 exceeding expectations. Recent developments include AI integration with Anthropic's Claude and FDA clearance for a testosterone assay, signaling innovation in diagnostics and life sciences.
The outlook remains positive with strong analyst support (51.72% buy ratings) and a consensus price target of $111.43. Key risks include margin pressure from China divestment plans and weak academic demand. Revenue stability around $2.9B supports valuation, though high P/E of 53.47 requires sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
